Nektar Therapeutics · NASDAQ:NKTR

Zalevsky Jonathan sold 5,681 Nektar Therapeutics shares (Form 4)

Traded Jun 30, 2026 · Filed Jul 2, 2026

On Jun 30, 2026, Zalevsky Jonathan (Chief R&D Officer) sold 5,681 Nektar Therapeutics shares at US$70.00 for US$398K under a trading plan, leaving 9,756 shares. Filed Jul 2, 2026 (Form 4).

Sold
5,681 shares
Price
US$70.00
Value
US$398K
Holding after
9,756 shares
Trading plan
Yes (Made under a plan set in advance)
Role
Chief R&D Officer

The filing in full

DateSecurityTransactionSharesPriceHolding afterOwnership
Jun 30, 2026Common StockSale5,681US$70.009,756Direct

Source

View original at SEC

Related